Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      We conducted a pilot study of dose-dense epirubicin/cyclophosphamide (EC) x 6 --> paclitaxel (P) x 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) x 6 with filgrastim --> by weekly paclitaxel alternating with docetaxel x 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase). Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility.

      Related collections

      Author and article information

      Affiliations
      [1 ] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. dangc@mskcc.org
      Journal
      Clin. Breast Cancer
      Clinical breast cancer
      1526-8209
      1526-8209
      Oct 2008
      : 8
      : 5
      18952555
      S1526-8209(11)70538-9
      10.3816/CBC.2008.n.050

      Comments

      Comment on this article